Dexketoprofen

Drug Profile

Dexketoprofen

Alternative Names: Arveles; D 1158; Desketo; Dexketoprofen trometamol; Dexketoprofen tromethamine; Dextroketoprofen; Enangel; Enantyum; Keral; Ketesse; LM 1158; Nosatel; Quiralam; Quirgel; S-ketoprofen; Stadium; Sympal; Viaxal

Latest Information Update: 29 Sep 2014

Price : $50

At a glance

  • Originator Menarini
  • Developer Berlin Chemie; Celltech Group; Istituto Lusofarmaco; Malesci; Menarini
  • Class Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Inflammation; Musculoskeletal pain; Pain

Most Recent Events

  • 01 May 2014 Menarini completes a phase I bioavailability trial in volunteers in United Kingdom (NCT02209454)
  • 01 Apr 2014 Menarini initiates a phase I bioavailability trial in volunteers in United Kingdom (NCT02209454)
  • 30 Dec 2003 A case report has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top